(Drug Information Association: Horsham, Pennsylvania) -- The Drug Information Association (DIA), in collaboration with the U.S. Food and Drug Association (FDA), the Medical Imaging Contrast Agent Association, the Council on Radionuclides and Radiopharmaceuticals, and the American Medical Informatics Association, will host “Medical Imaging Continuum: Path Forward for Advancing the Uses of Medical Imaging in the Development of New Biopharmaceutical Products,” October 2–3, 2008 in Bethesda, Maryland.
This conference will provide updates on the harmonization and standardization of the key elements required to meet the FDA review process and Proposed Draft Regulatory Guidance of 2011.
Attendees will discuss “Metrics for Quantifying the Quality of Imaging Enterprises in Clinical Trials” and “Standardizing Image Acquisition, Transfer, and Analysis.” Potential outcomes will include:
- Endorsement of a rigorously defined metrics that quantify the quality of imaging enterprises in biopharmaceutical development
- An explanation of the issues surrounding the quantification of adjudication rates across therapeutic areas and imaging technologies
- Harmonization of imaging as a quantitative measure of drug-induced changes in multicenter clinical trials
- The adoption of a standard, open-source, internet-based application for transferring data from sites of acquisition to central repositories
“Working alongside experts from academia, professional imaging societies, nonprofit consortia, and governmental agencies’ meeting attendees will help to shape best practices for standardized medical imaging in clinical trials,” notes program chair P. David Mozley, M.D., senior director, imaging, Merck Research Laboratories.
For more information, visit www.diahome.org.
Add new comment